Humacyte (HUMA) FCF Margin (2020 - 2026)
Humacyte (HUMA) reported FCF Margin of 5106.87% for Q1 2026, up 46915.0% year-over-year from N/an in Q1 2025, and up 8.7% quarter-over-quarter from 5593.36% in Q4 2025.
Humacyte (HUMA) FCF Margin (2020 - 2026) Analysis & Trends
Humacyte (HUMA) has 4 years of FCF Margin data on file, last reported at 5106.87% in Q1 2026.
- FCF Margin for Q1 2026 came in at 5106.87%, up 46915.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 5076.14% (up 1441361.0% YoY), and the FY2025 annual result was 5195.49%, changed N/A from the prior year.
- FCF Margin grew to 5106.87% in Q1 2026 per HUMA's latest filing, from 5593.36% in the prior quarter.
- Over five years, FCF Margin peaked at 3181.01% in Q3 2025 and troughed at 8964.12% in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - | - |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - | - |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - | - |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn | -3.98% |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - | - |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - | - |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn | 43.35% |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - | - |
| 10 | Humacyte | 267.09 Mn | 218.55 Mn | -1.54 Mn | -5,106.87% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -5,106.87% |
| Dec 31, 2025 | -5,593.36% |
| Sep 30, 2025 | -3,181.01% |
| Jun 30, 2025 | -8,964.12% |
| Mar 31, 2025 | -5,576.02% |
| Sep 30, 2021 | -12,673.03% |
| Sep 30, 2020 | -1.97% |